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Abstract
This review addresses selected aspects of the management of severe healthcare-associated infections due to methicillin-resistant Staphy-
lococcus aureus (MRSA), including the limitations of current therapy, potential alternative agents, new therapeutic options, clinical
approaches to MRSA bacteraemia/endocarditis and ventilator-associated pneumonia, and strategies to improve outcomes in patients
with severe MRSA infections.
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Introduction
In this decade, there has been a continuous increase in the
incidence of methicillin-resistant Staphylococcus aureus (MRSA)
in Europe and the USA, and the latter has witnessed the emer-
gence and dissemination of community-acquired infections due
to MRSA. However, an unprecedented decline in MRSA infec-
tion rates in several European countries has recently been
observed (UK, France, Belgium, Denmark, Finland, Turkey,
Cyprus, Slovenia and Austria), whereas other large countries,
such as Germany and Spain, have managed to stabilize the inci-
dence of MRSA [1,2]. This good news indicates that, for the
ﬁrst time, a diverse group of European countries with varying
baseline prevalences of MRSA was capable of reversing the
worrisome trend of inexorably increasing rates of MRSA. The
reasons for the observed decline are numerous and beyond
the scope of the current review. Clearly, these recent ﬁndings
suggest that the spread of MRSA can be curbed in hospitals,
provided that active control programmes are implemented.
For instance, following the introduction of speciﬁc pro-
grammes for limiting cross-transmission, ﬁrst at regional levels
and subsequently at national levels, MRSA infection rates
decreased by almost 50% between 1993 and 2006 in hospitals
of the Paris region (Assistance Publique-Hoˆpitaux de Paris)
and by 20% since 2001 in more than 50 hospitals across
France.
The proportion of S. aureus infections due to MRSA is
increasing, and S. aureus infections are increasingly being
acquired in the community. In addition, there is growing
evidence that patients with MRSA bacteraemia have a worse
outcome than similar patients with infections due to methi-
cillin-susceptible S. aureus (MSSA) [3]. New antimicrobial
agents and new management methods are thus needed.
This review addresses selected aspects of the management
of severe healthcare-associated MRSA infections, including
the limitations of the current therapy, potential alternative
agents, new therapeutic options, clinical approaches to MRSA
bacteraemia/endocarditis and ventilator-associated pneumo-
nia (VAP), and strategies to improve outcomes in patients
with severe MRSA infections. Community-acquired MRSA
infections in Europe are, at the moment of writing, still rare,
and therefore will not be addressed; selected aspects of
infection prevention and MRSA control are dealt with in the
companion articles of this theme section. Although a number
of important citations are included, they are by no means
exhaustive, and the reader is referred to other sources for
further evidence.
Limitations of Current Therapy
Glycopeptides have been the mainstay of treatment for
MRSA infections and staphylococcal infections in patients
with true penicillin allergy. Glycopeptides are less bactericidal
than b-lactam agents, and penetration into tissues is poor.
Vancomycin has been reported to clear bacteraemia
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in patients with endocarditis more slowly than b-lactams, i.e.
7 days vs. 3.4 days in nafcillin-treated patients [4], and has
been found to be associated with higher infection-related
mortality than b-lactams in treatment of endocarditis caused
by MSSA [5]. For these and other reasons, a number of
recent reports have called into question the efﬁcacy of this
class of antimicrobials in the treatment of severe MRSA
infections. Higher rates of relapse, complications, treatment
failure and mortality in cases of MRSA bacteraemia and
endocarditis have been associated with vancomycin therapy.
Increasing the dose of vancomycin may not safely overcome
its limited bactericidal activity, and its combination with a
second antistaphylococcal agent does not improve its thera-
peutic efﬁcacy (mortality being the outcome measure). MRSA
strains with lower vancomycin MIC values have been associ-
ated with increased rates of treatment success with vanco-
mycin as compared with strains that have higher vancomycin
MIC values, whereas increased MICs of vancomycin for
S. aureus may be predictive of increased treatment failure
(30-day mortality) and longer duration of bacteraemia in
patients receiving vancomycin therapy [6,7].
Decreasing activity of glycopeptide antimicrobials
Despite more than 50 years of treatment with vancomcyin,
fully vancomycin-resistant strains (vancomycin-resistant
S. aureus (VRSA)) are still an anecdotal phenomenon, with
fewer than ten strains having been described, mainly in the
USA, but also abroad [8,9]. These strains have been associ-
ated with only limited clinical consequences, because they
have not been associated with invasive disease.
VRSA and vancomycin-intermediate S. aureus (VISA) are
usually cross-resistant to teicoplanin [10]. VISA and hetero-
resistant VISA strains of S. aureus that contain subpopulations
of daughter cells displaying intermediate sensitivity to vanco-
mycin, but for which the MICs of vancomycin fall within the
susceptible range, can be difﬁcult to detect in the microbiol-
ogy laboratory, because the phenotypes are unstable and can
be lost on subsequent passages.
The role of tolerance to vancomycin in S. aureus has not
been well clariﬁed. It is more frequently associated with
MRSA than with MSSA and in isolates from patients with
endocarditis [11]. Whether tolerance is a prerequisite for
attenuated vancomycin efﬁcacy and the development of gly-
copeptide resistance warrants further study. Part of the
intermediate glycopeptide resistance seen in VISA may be
due to tolerance [12]. Several small series and case studies
have reported poor clinical response to vancomycin in the
treatment of bacteraemia/endocarditis caused by vancomy-
cin-tolerant S. aureus and the need for additional agents for a
bactericidal effect [13–15].
Teicoplanin is used in several European countries as the
main glycopeptide. The MIC90 of teicoplanin is greater than
that of vancomycin. The protein-binding ability of teicoplanin is
approximately 92%; however, bactericidal activity depends on
the total drug level of teicoplanin rather than on the concen-
tration of the free drug. Teicoplanin is usually seriously under-
dosed, and a loading dose is needed. Trough concentrations
should be maintained at c. 20 mg/L. Teicoplanin-intermediate
S. aureus may now be more common than VISA, but its clinical
impact has not been studied systematically.
There is growing evidence of a vancomycin MIC creep in
various MRSA isolates. For example, a study from UCLA
Medical Center showed that, among the 6002 clinically rele-
vant MRSA isolates tested, there was a shift in vancomycin
MICs from £0.5 to 1.0 mg/L during the 5-year study period.
The percentage of S. aureus isolates with a vancomycin MIC
of >1 mg/L in 2004 was signiﬁcantly higher than the percent-
age of isolates in 2000 (70.4% vs. 19.9%; p <0.01). This shift
in vancomycin MIC value was more notable in MSSA [16].
In another recent study from the south of the USA, 90% of
the strains demonstrated vancomycin MICs of >2.0 mg/L
according to Etest, and 12% demonstrated a vancomycin
MIC of 3.0 mg/L [17].
Most unfortunately, there is a poor correlation between
MICs obtained by Etest and those obtained by microdilution
procedures, and MICs may vary signiﬁcantly between two
different determinations. It is important to realize the impor-
tant limitations of the clinical laboratory in detecting reduced
susceptibility and resistance to vancomycin, and the reader is
referred to the review in this issue by Struelens et al. for fur-
ther discussion. On the other hand, it should be realized that
vancomycin creep is not a universal phenomenon, and that
vancomycin MICs have been found to be stable over time by
other investigators [18,19].
There is some evidence for the clinical impact of increased
vancomycin MICs. The vancomycin success rate in treating
MRSA bacteraemia was found to be much higher for isolates
with MICs of £0.5 mg/L (56%) than for isolates with MIC values
of 1.0–2.0 mg/L (10%) [7,20]. Also, in a recent study from
Spain, mortality associated with MRSA bacteraemia was signiﬁ-
cantly higher when vancomycin was used empirically for treat-
ment of infection with strains with a high vancomycin MIC
(>1 mg/L) [21]. Other recent reports have linked clinical failure
with vancomycin treatment of infections involving strains with
MICs of 2–4 mg/L or heteroresistant VISA strains [6,7,20–23].
The CLSI therefore lowered the vancomycin breakpoint for
S. aureus susceptibility from 4 to 2 mg/L in 2006.
Clinical MRSA strains with high vancomycin MIC values
(2 mg/L) require aggressive empirical therapy to achieve
trough concentrations ‡15 mg/L.
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This can be achieved with continuous perfusion of vanco-
mycin, a concept that has become popular in many European
countries, in particular in the intensive-care unit (ICU) set-
ting. However, not all studies were able to show that achiev-
ing a vancomycin trough in excess of 15 mg/L improved
success rates [6].
In summary, vancomycin is recommended for empirical
therapy in healthcare settings with an increased incidence of
methicillin-resistant staphylococci or when risk factors for
MRSA infections are present, such as MRSA-positive surveil-
lance cultures. Although high-level resistance remains rare,
data from some centres suggest an evolutionary change in
S. aureus, as evidenced by reduced susceptibility to vancomy-
cin. This, together with the problem of heteroresistance to
vancomycin, as well as poor tissue penetration after systemic
administration, presents potential obstacles to the successful
treatment of S. aureus infections with this glycopeptide.
Although it has been suggested that these problems may be
overcome by administration of vancomycin in much higher
doses by continuous perfusion, the efﬁcacy and safety of this
approach remain to be determined.
The subgroup of patients with infections due to strains
with vancomycin MIC values of >1 mg/L can be managed by
alternative therapy, with the combination of vancomycin and
other drugs, or by providing doses of vancomycin high
enough to achieve trough levels >15 mg/L. However, the risk
with higher dosages is an increase in nephrotoxicity.
Classic Alternatives to Standard Therapy
Trimethoprim–sulphamethoxazole
Trimethoprim–sulphamethoxazole is inexpensive and suitable
for sequential therapy. A high proportion of in vitro MRSA
isolates susceptible to trimethoprim–sulphamethoxazole have
been reported recently [24]. In the animal model, folate
antagonist treatment fails when delayed, consistent with the
possibility that in vivo thymidine release inhibits folate antago-
nists.
Trimethoprim–sulphamethoxazole can be regarded as a
second-line agent for the treatment of severe MRSA infec-
tions in patients unable to tolerate other more active drugs,
such as glycopeptides or linezolid. In a randomized, prospec-
tive trial comparing trimethoprim–sulphamethoxazole with
vancomycin [25] in intravenous drug abusers with endovas-
cular infections caused by MSSA and MRSA (47% MRSA), tri-
methoprim–sulphamethoxazole was inferior to vancomycin
in terms of duration of bacteraemia (6.7 vs. 4.3 days), sterili-
zation of wound cultures (5.8 vs. 3.8 days), duration of fever,
and failure rates (six of 43 patients treated with trimetho-
prim–sulphamethoxazole vs. one of 58 patients treated with
vancomycin). If trimethoprim–sulphamethoxazole is selected,
intravascular infections and infections with abscesses or a
high degree of necrotic tissue must not be considered
for treatment, because the availability of exogenous thymi-
dine may inactivate trimethoprim–sulphamethoxazole as it
bypasses the double biosynthetic blockade. Trimethoprim–
sulphamethoxazole may be better suited for infections with a
low bacterial burden, as is the case for chronic osteomyelitis
and clinical situations with no risk of death in case of clinical
failure.
Chloramphenicol
A very high proportion of MRSA isolates in different areas of
the world remain susceptible to chloramphenicol, including
community-acquired isolates. In a SENTRY study, 82% of the
MRSA isolates from cases of pneumonia were chlorampheni-
col-susceptible [26]. In six sequential multicentre national
studies of Staphylococcus performed in Spain from 1986
to 2006, the rates of chloramphenicol susceptibility rose
from 92% to 98% [27]. Treatment with chloramphenicol in
association with vancomycin has shown an antagonistic effect
in vitro [28]. Unfortunately, both the potential myelotoxicity
of chloramphenicol and the absence of reported recent
clinical experience with its use in the treatment of MRSA
infections make it a possibility only as a last resort in
situations where no better alternatives are available.
Tetracyclines
The long-acting tetracyclines doxycycline and minocycline are
well absorbed by the gastrointestinal tract, have very good
tissue penetration, and have better antistaphylococcal activity
than tetracycline. In vitro data suggest that minocycline has
better antistaphylococcal activity than doxycycline [29], but
clinical superiority has not been demonstrated. The data
available are insufﬁcient to support their use in serious infec-
tions such as bacteraemia or endocarditis.
Synercid
The streptogramin combination quinupristin–dalfopristin
(Synercid) has synergistic antibacterial activity in vitro against
a wide array of Gram-positive organisms, including a high
proportion of MRSA strains. It has proven effective in animal
models of infection (bacteraemia and endocarditis) caused by
MRSA. Its clinical use is limited, because administration is via
slow infusion of a large volume, and it inhibits P450 3A4 and
can inhibit agents metabolized through this pathway. Arthral-
gia and myalgia are among the main adverse events associ-
ated with Synercid. Pain and inﬂammation at the infusion
site occur in up to 75% of patients. The drug can also cause
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hyperbilirubinaemia and liver toxicity and, by interfering with
the metabolism of other drugs, may induce QTc prolonga-
tion. Synercid has been found to be equivalent to other
agents for the treatment of skin and soft tissue infections,
but it was inferior to comparators for the treatment of
pneumonia and infective endocarditis [30]. The present sta-
tus of synercid is that it did not acquire regulatory approval
by the FDA for the treatment of MRSA infections. The wide
spectrum of adverse effects makes synercid an inferior
choice for the treatment of MRSA infections. An in-depth
review of the role of antistaphylococcal agents, including
fusidic acid, fosfomycin, and others, by Bouza [31] will be
available in an upcoming supplement to CMI.
Antibiotic combinations
The combination of vancomycin and aminoglycosides is syn-
ergistic against most infections due to MRSA. The synergism
of vancomycin and gentamicin is not predictable for MRSA
strains with gentamicin MIC values of 0.5 to >128 mg/L [32].
Combination therapy might confer a small advantage in cases
of staphylococcal prosthetic valve endocarditis, in accordance
with most animal model data, because, after adjustment for
duration of treatment by logistic regression analysis, valves
from patients with staphylococcal endocarditis receiving any
kind of combination therapy were six times more likely to
be culture-negative than those receiving monotherapy [33].
Combination regimens involving aminoglycosides have dem-
onstrated a more rapid clinical response and a reduced dura-
tion of bacteraemia. Current guidelines for the treatment of
S. aureus endocarditis recommend the use of a 4–6-week
course of vancomycin or an antistaphylococcal b-lactam,
with the optional addition of gentamicin (three times daily).
The addition of a single high dose of gentamicin at the
start of therapy may help to overcome the inoculum effect
associated with vancomycin, as bacterial densities approach
6 log10 CFU/mL within 24 h. A single high dose of genta-
micin in combination with vancomycin may be useful in
maximizing synergistic and bactericidal activity and in
minimizing toxicity. There have been no studies in humans
with S. aureus infective endocarditis (IE) demonstrating that
early bactericidal activity improves reduction in metastatic
complications or mitigation of valvular damage. Therefore,
further in vivo studies must be performed in order to
determine its appropriateness for clinical practice. In any
case, the association of vancomycin and gentamicin should
be used with caution in patients with MRSA infections, and
should be undertaken for a very short period of time, to
avoid nephrotoxicity.
The combination of vancomycin with rifampin should
also be considered in the treatment of MRSA endocarditis.
Studies of in vitro and in vivo bactericidal interactions of
vancomycin plus rifampin in treating S. aureus infections
have yielded conﬂicting results. In vitro results concerning
interactions between rifampin and other antibiotics are
method-dependent, and often do not correlate with in vivo
ﬁndings. In the rabbit model of left-sided endocarditis due to
MRSA, vancomycin alone and vancomycin plus rifampin were
equally effective in reducing mortality and in sterilizing renal
abscesses [34]. In the only prospective trial of rifampin as an
adjunct to traditional therapy for S. aureus endocarditis, rifam-
pin in combination with vancomycin for treatment of MRSA
endocarditis was not beneﬁcial, either in increasing survival
or in decreasing the duration of bacteraemia, although the
study sample was too small to endorse one regimen over the
other [35]. Some results even suggest that the potential for
hepatotoxicity, drug–drug interactions and the emergence of
resistant S. aureus isolates warrants a careful risk–beneﬁt
assessment before rifampin is added to standard antibiotics
for the treatment of severe S. aureus infections [36]. Given
the prevalence of staphylococcal infections and the limited
number of treatment options, further adequately powered
studies of rifampin as adjunctive therapy are needed.
The combination of fosfomycin and imipenem has been
found to be highly synergistic and bactericidal against MRSA.
In the humanized model of left-sided endocarditis due to
MRSA, the combination is consistently more effective in ster-
ilizing the vegetations and in reducing the log of CFU/g of
vegetation than either drug used alone or vancomycin. These
data indicate that this combination deserves consideration
for clinical application (Garcı´a de la Marı´a C, Marco F, Miro´
JM, et al. Program and abstracts of the 43rd Annual Inter-
science Conference on Antimicrobial Agents and Chemo-
therapy, Chicago, 2003. Abstract B-1091).
New Therapeutic Options
As stated above, low-dose vancomycin may be inferior to
some new comparator agents in the treatment of serious
MRSA infections, especially in the presence of increased MIC
values. Novel agents with activity against MRSA have become
available in Europe in recent years, and others are in the
advanced stage of clinical development. In some instances,
although most comparative trials with these new agents have
important limitations in their design, some indirect evidence
of their possible superiority over vancomycin is emerging.
Daptomycin
Daptomycin, a new lipopeptide already present in nature
30 million years ago, has a unique mechanism of action,
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and is only active against Gram-positive bacteria. It acts at
the cytoplasmic membrane, binding but not penetrating the
membrane via a calcium-dependent insertion of its lipid
tail. Cell death occurs in association with widespread
inhibition of the synthesis of DNA, RNA, and protein, but
cell lysis and the release of large molecules from the
cytoplasm does not occur. Daptomycin susceptibility is
deﬁned as an MIC of <1 mg/L (CSLI 2006). Among
S. aureus strains fully susceptible to vancomycin, 97% are
susceptible to daptomycin. With the emergence of an
increasing number of strains of S. aureus with vancomycin-
intermediate susceptibility, a correlation has been noted
between acquisition of vancomycin-intermediate susceptibil-
ity and non-susceptibility to daptomycin. Among strains
with a vancomycin MIC value of 4 mg/L, only 20% are
susceptible to daptomycin, and among strains with a
vancomycin MIC value of 8–16 mg/L, only 7% are suscepti-
ble to daptomycin [37]. Among the ﬁrst seven VRSA iso-
lates (vancomycin MIC ‡32 mg/L), all but one remain
susceptible to daptomycin [8].
Daptomycin heteroresistance is also found among strains
that develop vancomycin heteroresistance during treatment
with vancomycin, even when the MIC for the organisms
remains within the susceptible range. In vitro killing assays
demonstrate less rapid killing of these heteroresistant iso-
lates [38]. A strong correlation (R = 0.814, p 0.0001) has
been found between reduced susceptibility to daptomycin
and vancomycin resistance among VISA strains, and this loss
of susceptibility correlates with the degree of cell wall thick-
ening (R = 0.883, p <0.0001) [39]. It has been postulated that
the mechanism of the loss of daptomycin susceptibility is due
to the inability of daptomycin to pass through the physical
barrier of the enlarged cell wall [39]. In clinical isolates, prior
patient exposure to vancomycin is associated with isolates
with a small but statistically signiﬁcant rise in daptomycin
MIC values (mean 0.599 vs. 0.726 mg/L, p 0.019), even
among strains that remain within the susceptible range
(Moise-Broder P, El-Fawal N, Forrest A, et al. 2006. Program
and abstracts of the 46th Annual Interscience Conference on
Antimicrobial Agents and Chemotherapy. Washington DC:
ASM. Abstract C2-1151)[40].
The daptomycin half-life is approximately 8 h, with a
volume of distribution of 100 mL/kg, and protein binding of
90–93%, which is independent of dose. Protein binding is
reduced to 84–88% among patients with a creatinine clear-
ance of <20 mL/min. Approximately 78% of daptomycin is
excreted via the kidney, two-thirds as intact drug. It is not
extensively metabolized. In in vitro time-kill studies using
exponential growth phase MRSA, there is more than a
3 log10 fall in CFU/mL within only 2 h at a 20 mg/L concen-
tration of daptomycin, as compared to a less than 1 log10 fall
with 20 mg/L vancomycin. It has concentration-dependent
killing activity in vitro and in pharmacodynamic studies in
mice. It produces a post-antibiotic effect of over 6 h at
16 mg/L, which is concentration-dependent, as compared
with a 1.3–1.8 h post-antibiotic effect of vancomycin, which
is non-dose-dependent [41]. Unlike vancomycin, it maintains
a high level of bactericidal activity when tested against a high
inoculum of 9.5 log10 CFU/g of MRSA in an in vitro simulated
endocardial vegetation model, and has activity against station-
ary-phase organisms [42,43].
S. aureus non-susceptibility to daptomycin after vancomy-
cin treatment is a source of considerable concern. Clinical
cases showing decreasing susceptibility of S. aureus to vanco-
mycin due to antibiotic pressure exerted by daptomycin, or
vice versa, and showing treatment failure have been
reported. Rose et al. [44] evaluated the resistance of dapto-
mycin after exposure to vancomycin in clinical S. aureus iso-
lates (four MRSA isolates and one MSSA isolate), using an
in vitro pharmacokinetic/pharmacodynamic model. Their
results demonstrate that reduced daptomycin susceptibility is
an unstable event and is strain-speciﬁc. With the exception
of vancomycin, reduced susceptibility to daptomycin due to
prior treatment with other antibiotics has not been
reported.
Minimal skeletal muscle toxicity is rarely seen with the
current dosage. It is predicted by elevations in serum creati-
nine phosphokinase and is reversible upon discontinuation of
treatment. No signs of toxicity in cardiac or smooth muscle
have been reported. Other side effects related to daptomy-
cin are unusual and have not been associated with signiﬁcant
increases in adverse events as compared to comparator arms
in randomized trials. Exceptions are events related to the
peripheral nervous system, including paresthesias, dysesthesia
and peripheral neuropathy, which were observed in 9.2% of
patients receiving daptomycin in the bacteraemia trial, as
compared with 1.7% of patients in the comparator arm
(p 0.02). These events were transient and resolved during
continued treatment [69]. Daptomycin would be a drug of
choice for patients with MRSA bacteraemia who are either
intolerant to vancomcyin or infected with daptomycin-sus-
ceptible strains of VRSA.
Daptomycin has been prospectively compared with stan-
dard therapy in patients with S. aureus bacteraemia and/or
right-sided endocarditis. The success rates were similar in
patients with MRSA isolates. Daptomycin, however, was
associated with a higher rate of microbiological failure than
was standard therapy. Some of the isolates of the patients
classiﬁed as microbiological failures developed reduced sus-
ceptibility to daptomycin.
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Renal dysfunction occurred more frequently in the
patients receiving vancomycin rather than daptomycin (26%
vs. 11%) [45].
Daptomycin should not be used for treating patients with
pneumonia, because of the lack of efﬁcacy due to inactivation
of the drug by lung surfactant. Resistance to daptomycin is
uncommon, but can be induced by serial passage in the pres-
ence of increasing concentrations of the antibiotic. Clinically,
resistance occurs in patients who receive prolonged courses
of treatment [46,47].
Daptomycin is approved in the European Union for the
treatment of complicated skin and skin structure infections
(cSSSIs), right-sided endocarditis due to S. aureus, and
S. aureus bacteraemia associated with right-sided endocarditis
or cSSSIs [48].
Linezolid
Linezolid, the ﬁrst available agent in the new class of oxazolidi-
none antibiotics, represents a signiﬁcant advance in the man-
agement options available for combating MRSA infections.
Linezolid has a unique mechanism of action whereby it selec-
tively binds to the 50S ribosomal unit and prevents formation
of the initiation complex. This action is thought to prevent
cross-resistance with other antimicrobial agents. Protein bind-
ing is low. This agent is bacteriostatic against staphylococci,
and has an MIC90 of 2 mg/L against MRSA [49].
The oral bioavailability of linezolid is approximately 100%,
thus allowing sequential intravenous-to-oral administration
without changing the drug or dosage regimen. In a multi-
national, randomized, phase III trial, linezolid recipients, as
compared with vancomycin recipients, had a median length
of hospitalization that was 5–8 days shorter; there were
more discharges during the ﬁrst week of treatment, and
fewer days of intravenous therapy [50]. Retrospective pooled
analysis and simultaneous meta-analysis of ﬁve prospective,
randomized, controlled studies demonstrated that linezolid
was associated with outcomes that were not inferior to
those obtained with treatment with vancomycin in 144
patients with S. aureus bacteraemia, including patients with
MRSA bacteraemia [51]. Linezolid has been used successfully
in the treatment of IE caused by resistant Gram-positive
cocci. The studies, however, were retrospective, and repre-
sent daily clinical practice; in many cases of IE, the patients
were those failing with other drugs or those in whom linezo-
lid was introduced sequentially after other primary therapy.
The question of using a bacteriostatic antibiotic for the treat-
ment of IE remains contrary to classic principles. Conversely,
in a large randomized study in patients with catheter-related
bacteraemia, there was an excess number of deaths in the
linezolid arm, mainly due to Gram-negative bacillary infec-
tions [52], and therefore it has not been approved by the
FDA for treatment of catheter-related bacteraemia or endo-
carditis.
Although it is generally well tolerated, adverse effects as a
result of treatment with linezolid can be serious. Gastroin-
testinal adverse effects are relatively common. Bone marrow
suppression, especially thrombocytopenia, is the most com-
mon serious adverse effect. Both peripheral and optic neu-
ropathy have been reported with prolonged use (more than
28 days). Linezolid has a weak activity as a monoamine oxi-
dase inhibitor and, when it is given to patients with serotonin
re-uptake inhibitors, these patients may develop the seroto-
nin syndrome.
Tigecycline
Glycylcyclines comprise a novel group of antimicrobial
agents. These agents retain a central four-ring carbocyclic
skeleton of the tetracycline class that is crucial for antimicro-
bial activity. Tigecycline has a 9-t-butyl-glycylamido side chain
on the central skeleton. Active efﬂux of drugs from inside
the bacterial cell, and ribosomal protection, are the two
main mechanisms of bacterial resistance to tetracyclines.
Tigecycline most likely overcomes these tetracycline resis-
tance mechanisms through steric hindrance by a large substi-
tuent at position 9.
Tigecycline is bacteriostatic against MRSA (MIC90 0.5 mg/
L) and has in vitro activity against VISA and VRSA
(MIC90 £0.5 mg/L) [53].
In a rat model of aortic MRSA endocarditis, a reduction
of more than 4 log10 CFUs of the MRSA isolate was
reported. In this experimental model, tigecycline was more
effective than vancomycin in reducing bacterial colony counts
at a lower dose [54].
Tigecycline is available only as an injectable antibiotic, and
is administered twice daily as a 1-h infusion. Tigecycline has a
large and variable volume of distribution, which has been
found to range from c. 5 to >10 L/kg; this is signiﬁcantly
greater than what has been determined for currently avail-
able tetracyclines.
The most frequently reported adverse events associated
with tigecycline are nausea, vomiting, and headache. Although
the frequency of these events is high, the severity is low, and
the overall rate of treatment discontinuation because of
nausea in the phase III studies was <1.5%. Experience with
currently marketed tetracyclines may suggest other adverse
effects due to tigecycline, e.g. deposition in teeth and bone
during calciﬁcation, and drug interactions with antacids, anti-
coagulants, and other agents.
At the time of writing, only two double-blind trials of
tigecycline for the treatment of MRSA infections have been
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published; both studies concerned cSSSIs, and vancomycin
was used as the comparator.
No published experience is available concerning patients
with MRSA bacteraemia/endocarditis or MRSA pneumonia. It
appears that the target AUC for tigecycline should be two
to four times the MIC. As the MIC90 range for MRSA is
0.25–0.5 mg/L, caution should be exercised when using tige-
cycline for the treatment of bacteraemia [55]. It is approved
in the European Union for the treatment of cSSSIs and com-
plicated intra-abdominal infections.
Tigecycline may be considered as alternative empirical
therapy for patients with mild-to-moderate cSSSIs and for
complicated intra-abdominal infections. The main issue
regarding MRSA infections, however, concerns the role of
tigecycline in the treatment of other severe infections caused
by MRSA, including nosocomial pneumonia, bacteraemia,
catheter-related bloodstream infections, and bone and joint
infections. A trial comparing tigecycline with imipenem–cilast-
atin in the treatment of nosocomial pneumonia ended
recently, but full information is not yet available as a pub-
lished report. Tigecycline failed to achieve the non-inferiority
results (Maroko R, Cooper A, Dukart G et al. 47th Annual
Interscience Conference on Antimicrobial Agents and Che-
motherapy, Abstract L-730, Chicago, 2007) [56].
Clinical Approach to MRSA Bacteraemia
and Endocarditis
S. aureus bacteraemia and endocarditis are serious infections
that require prompt attention and pertinent clinical decisions
to improve outcomes. Currently, S. aureus is a leading cause
of healthcare-associated bloodstream infections and, accord-
ingly, the ﬁrst cause of IE in most regions of the developed
world. A convincing amount of experience indicates an
increased risk of death for patients with MRSA bacteraemia,
as compared with the risk for similar patients with MSSA
bacteraemia [3,57], and reveals high mortality rates among
patients with left-sided MRSA endocarditis. Thus, the man-
agement of bacteraemia and endocarditis caused by MRSA
should be regarded as a growing clinical challenge.
Establishing the source and the extent of the infection,
and initiating appropriate empirical antibiotic therapy, are the
most important aspects of the clinical approach. Most
patients have an identiﬁable underlying focus of infection at
the time of initial evaluation, but the source of infection is
uncertain in the remaining patients. The most common
sources of MRSA bacteraemia are intravenous catheters and
other intravascular devices, skin and soft tissue infections,
and VAP [58]. Approximately one-third of patients with
MRSA bacteraemia, either primary or secondary, will develop
metastatic complications, including involvement of heart
valves, intervertebral discs, intra-abdominal organs, and
bones and joints, especially when prosthetic material is pres-
ent [59]. In the clinical setting, it can be difﬁcult to establish
whether an infected organ is the primary source of the sec-
ondary bacteraemia or whether an organ was secondarily
infected from a primary bacteraemia. Identiﬁcation of the
infected sites is essential, and both a careful patient history
and a physical examination, including radiographic imaging
studies and echocardiography of the heart, are important.
Empirical antibiotic therapy should be established according
to the principles outlined in this review, and it should be
taken into account that delaying appropriate antibiotic ther-
apy for S. aureus bacteraemia beyond 48 h is associated with
increased mortality [60].
For the purposes of this review, three different clinical sit-
uations are considered:
Catheter-related bacteraemia
Recommendations for catheter management are similar
for bacteraemia due to MSSA and that due to MRSA. The
catheter should be removed as soon as the diagnosis of
catheter-related bacteraemia is considered. Prospective
studies have demonstrated that removal of an infected
central venous catheter (CVC) is associated with a more
rapid clinical response and a lower rate of recurrence than
maintenance of the infected CVC [61,62].
Furthermore, failure to remove the CVC or other
infected intravascular prosthetic material has been associated
with an almost doubled rate of mortality. Management
of tunelized catheters without catheter removal, using both
systemic and local (antibiotic-lock technique) antimicrobial
treatments, should be reserved for very unusual circum-
stances and selected patients.
Empirical antibiotic treatment should be initiated with
vancomycin, i.e. the standard therapy. Teicoplanin is another
option, as randomized studies in cancer patients with CVC-
related bacteraemia have shown similar clinical and microbio-
logical outcomes with both glycopeptides [63]. A switch to
daptomycin therapy may be considered in patients with slow
response, persistent bacteraemia, or worsening renal func-
tion, or in those infected with VISA strains. It should also be
considered in situations in which a signiﬁcant proportion of
MRSA isolates exhibit vancomycin MIC values of >1 mg/L.
On the other hand, a switch to oral linezolid therapy may
be considered in patients with a rapid response and negative
blood cultures after catheter removal. The duration of ther-
apy will depend on the presence of complications. If the
response is good and there is no evidence of a complicated
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course, patients can be safely discharged to complete 14 days
of therapy at home. There are no convincing data to support
recommending shorter treatment schedules in cases of
MRSA bacteraemia.
Complicated bacteraemia
Complicated bacteraemia is usually deﬁned as the presence
of metastatic infection during hospitalization, attributable
mortality, or recurrent infection during the follow-up per-
iod. The classical predictors of complicated bacteraemia are
community origin of the infection, absence of an identiﬁable
portal of entry, and persistence of fever; however, the
strongest indicator is persistent bacteraemia, deﬁned as a
positive result with blood cultures performed 3–4 days
after the initiation of therapy [58]. Persistent bacteraemia
(PB), a characteristic feature of S. aureus bloodstream infec-
tion, appears to be more frequent among MRSA-infected
patients. In fact, the recognized risk factors for PB are
maintenance of intravascular devices, chronic renal failure,
methicillin resistance, and vancomycin therapy. The pres-
ence of PB or any other clinical indicator of complicated
infection warrants a thorough search for endocarditis or
another metastatic focus of infection. In this context,
repeating blood cultures every 48–72 h and performing
trans-oesophageal echocardiography are mandatory [64].
Patients undergoing glycopeptide therapy with documented
PB or lack of clinical response should be treated with dap-
tomycin as the ﬁrst alternative. Results of in vitro suscepti-
bility testing and ﬁnal diagnosis of the complication
(endocarditis, espondilitis, endophthalmitis, etc.) should
guide the choice of deﬁnite therapy.
Endocarditis
Patients with left-sided MRSA endocarditis are more likely to
have chronic conditions (immunosuppressive therapy, main-
tenance haemodialysis and treatment of diabetes mellitus),
have healthcare-associated infections, or have persistent
bacteraemia. Mortality rates are higher, and may be as high
as 70%. Prosthetic endocarditis and denial of surgery when
indicated are associated with a worse prognosis.
Right-sided MRSA endocarditis is less frequent and affects
intravenous drug users; it is more often community acquired
and caused by community-associated MRSA genotypes. The
prognosis is better, with c. 15% mortality rates.
According to the current guidelines, in spite of the limited
efﬁcacy of the drug for this infection, vancomycin remains
the reference standard for the treatment of both prosthetic
and native right-sided and left-sided MRSA endocarditis.
Sometimes, gentamicin or rifampin is added to enhance bac-
tericidal activity; this possibility is mentioned in guidelines,
but not recommended speciﬁcally. Gentamicin is usually
added when MRSA strains are non-susceptible; there is no
evidence of increased efﬁcacy in terms of reducing mortality,
and the combination is often nephrotoxic. In the case of
rifampin, the combination may even be antagonistic, and
resistance may develop during therapy [35,36].
The consensus is that right-sided endocarditis can be
treated safely with vancomycin, 15 mg/kg/12 h/6 weeks
(achieving trough levels of 15–20 mg/L), while paying careful
attention to the patient’s evolving condition. In cases of
renal impairment, sustained bacteraemia for more than
7 days, or infection with a VISA strain, treatment should be
with daptomycin, 6 mg/kg/day or a higher daily dose, for
6 weeks.
Recommendations for treating left-sided MRSA endocardi-
tis are more complicated. The occurrence of treatment
failure with vancomycin should be regarded as very possible
from the beginning of therapy. Blood cultures should be per-
formed on a 2-day basis, early surgery should be considered
in every case, and MICs/MBCs of vancomycin, daptomycin
and all possible relevant alternatives should be investigated.
To date, the results obtained with either vancomycin or dap-
tomycin therapy, using standard doses, have been disappoint-
ing [45]. If treatment failure with vancomycin occurs, or the
infecting strain shows reduced vancomycin susceptibility, an
early switch to high-dose daptomycin therapy (10 mg/Kg/day)
is recommended, provided that the strain remains fully
susceptible to the drug. Patients who have been heavily
exposed to vancomycin may be at increased risk of a sub-
optimal response to daptomycin; accordingly, when indicated,
such switching should be performed as soon as possible.
Patients who fail to respond to these agents must be treated
with other antibiotic combinations on a compassionate basis
under expert evaluation. In this setting, linezolid or the
combination of high-dose fosfomycin and imipenem are
alternative choices, as discussed earlier.
Management of MRSA Vap
S. aureus is one of the leading causes of VAP in Europe. VAP
due to MRSA is rising in incidence and poses unique chal-
lenges for management. Risk factors for the development of
MRSA-related VAP include nasal carriage, prior antibiotic
therapy, prolonged mechanical ventilation, poor infection
control practices, head trauma/coma, and viral infection [65].
Data suggest that a diagnosis of MRSA-related VAP is an
important determinant of excess hospitalization and ICU
length of stay, as well as attributable costs, as compared with
MSSA infection [66].
132 Clinical Microbiology and Infection, Volume 15 Number 2, February 2009 CMI
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 125–136
Current management guidelines recommend glycopeptides
as the initial therapy for MRSA-related VAP. However, suc-
cess rates for vancomycin are low. This may be due to the
poor penetration of vancomycin into the lung, in particular
when using conventional, low-dose regimens. Antibiotic pen-
etration into tissues and ﬂuids at the speciﬁc site of infection,
rather than the concentration in serum, has been increasingly
recognized as being much more valuable in predicting
response to drugs.
For vancomycin and linezolid, the most important pharma-
cokinetic/pharmacodynamic parameter seems to be the 24-h
AUC, although both antibiotics demonstrate concentration
independence [42,43]. However, vancomycin at dosages that
achieve such levels may be associated with renal dysfunction,
especially when it is given concomitantly with other nephro-
toxic drugs [67].
Linezolid is an alternative to vancomycin for the treatment
of MRSA-related VAP. A post hoc analysis of two double-blind
trials of patients with MRSA nosocomial pneumonia found that
patients treated with linezolid had signiﬁcantly higher survival
rates than those treated with vancomycin [68]. This analysis
has been criticized on methodological grounds, speciﬁcally
because of a non-prespeciﬁed subgroup analysis, the heteroge-
neity of results in the separate studies, and the small numbers
of patients infected with MRSA (7.3% of the combined micro-
biologically evaluable population). However, linezolid may be
preferred if patients have renal insufﬁciency or are receiving
other nephrotoxic agents, or when infection is caused by a
strain with a vancomycin MIC value of ‡1.5 mg/L.
Strategies to Improve Outcome in MRSA
Infection
There is an urgent need to improve early diagnosis and
empirical treatment of severe MRSA infection. The recent
development of accurate molecular techniques to identify
blood culture isolates in a much shorter time frame than
that required for traditional phenotypic methods is one
more step towards achieving rapid diagnosis of MRSA bac-
teraemia. Indeed, rapid reporting of identiﬁcation and suscep-
tibility results for Staphylococcus spp. in blood culture is
expected to improve treatment and reduce the length of
hospitalization. Various types of molecular tests have been
considered for the rapid identiﬁcation and differentiation of
‘Gram-positive cocci in clusters’ as revealed by direct exami-
nation of positive blood cultures. Controlled trials will be
necessary to determine whether these techniques are sufﬁ-
ciently reliable to exclude pseudobacteraemia and contamina-
tion of the bloodstream by coagulase-negative staphylococci,
and ﬁnally, to impact on antibiotic treatment decisions and
patient outcomes [69].
Identiﬁcation of patients at high risk of hospital-acquired
MRSA infection is possible on the basis of clinical risk fac-
tors. Known risk factors for bacteraemia after MRSA coloni-
zation include recent antibiotic therapy, ICU stay, extended
length of stay, initial involvement of bones or joints, and
intravenous catheterization [70]. Individuals who are known
to have harboured MRSA for >1 year are at high risk of sub-
sequent MRSA infection, and this warrants intervention [71].
Although precise thresholds have not been established, it
seems prudent to prescribe an agent effective against MRSA
to patients with several risk factors for hospital-acquired
MRSA infection or to patients who have presumed severe
staphylococcal infections in settings where the prevalence of
MRSA is known to be ‡20%.
Patients with recurrent MRSA bloodstream infection, or
with a history of extended vancomycin exposure, should be
considered to be at high risk of infection with MRSA for
which vancomycin MIC values are elevated. Appropriate and
aggressive empirical therapy is required for these patients.
In some US centres, patients with bloodstream infections
due to MRSA with vancomycin MIC values of ‡1.5 mg/L have
responded poorly to vancomycin, and alternative anti-MRSA
therapies should be considered for these patients. Several
treatment options are summarized in Table 1.
Whether linezolid has a role in the treatment of staphy-
lococcal bacteraemia remains controversial, although, on
the basis of pooled analysis of ﬁve studies comparing
linezolid with vancomycin in patients with secondary
S. aureus bacteraemia, it was claimed that linezolid is non-
inferior to vancomycin. The incidence of adverse events
was similar between treatment groups [51]. Clearly, less
expensive bactericidal agents should be considered as
valuable alternatives to linezolid for the treatment of
MRSA bacteraemia.
The initial therapeutic approach to MRSA infection varies
with the circumstances of the diagnosis of suspected S. aureus
TABLE 1. Treatment options for severe infections due to
methicillin-resistant Staphylococcus aureus (MRSA)
Treatment option Clinical scenario
Glycopeptide
(trough level 15–20 mg/L)
Standard option for initial treatment, in particular
for sepsis that is not life-threatening, and MIC
£1 mg/L or unknown MIC
Change to daptomycin Slow response, complicated bacteraemia, relapse
or breakthrough MRSA bacteraemia and/or
MIC >1.0 mg/L. Check daptomycin MIC if
patient has had previous glycopeptide exposure
Initial daptomycin Sepsis is life-threatening, renal impairment,
known MIC >1.0 mg/L of glycopeptide (check
daptomycin MIC), and previous, optimally
conducted glycopeptide therapy
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infection. In any case, rapid measures should be taken to cul-
ture the microorganism. A rapid examination of retrieved
material with a Gram stain may guide empirical antibiotic ther-
apy. It should also take into account the patient’s underlying
conditions, the severity of infection, the suspected source of
infection, and the response to previous antibiotic therapy. In
the presence of an indwelling device or foreign body, it is cru-
cial to consider the need for removal of potentially infected
foreign bodies, or surgical debridement and drainage of any
necrotic areas or purulent collections.
In contrast to many other bacterial infections, S. aureus
infections often require a prolonged course of treatment
because of the risk of late-onset complications such as
abscesses, osteo-articular infection, and other secondary foci
due to haematogenous or direct seeding. In cases of docu-
mented bacteraemia, the recommended minimum duration
of treatment is at least 14 days, as short-course therapy is
currently not considered to be safe and effective.
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